With respect to the finding that overexpression of most TRIM members tightly correlated with low overall patient survival rates and disease recurrence, TRIMs represent attractive therapeutic targets and novel tumor markers for early diagnosis and risk assessment as well as therapy of CRC. This evidence concerns the gene TRAT1 and colorectal carcinoma.